Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats

0504778 - FGÚ 2020 RIV GB eng J - Journal Article
Neckář, Jan - Khan, M. A. H. - Gross, G. J. - Cyprová, Michaela - Hrdlička, Jaroslav - Kvasilová, A. - Falck, J. R. - Campbell, W. B. - Sedláková, Lenka - Škutová, Šárka - Olejníčková, Veronika - Gregorovičová, Martina - Sedmera, David - Kolář, František - Imig, J. D.
Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats.
Clinical science. Roč. 133, č. 8 (2019), s. 939-951. ISSN 0143-5221. E-ISSN 1470-8736
R&D Projects: GA MZd(CZ) NV15-27735A
Institutional support: RVO:67985823
Keywords : spontaneously hypertensive rat * myocardial infarction * blood pressure * congestive heart failure * epoxyeicosatrienoic acid
OECD category: Pathology
Impact factor: 5.223, year: 2019
Method of publishing: Limited access
https://doi.org/10.1042/CS20180728

Epoxyeicosatrienoic acids (EETs) and their synthetic analogs have cardiovascular protective effects. Here, we investigated the action of a novel EET analog EET-B on the progression of post-myocardial infarction (MI) heart failure in spontaneously hypertensive rats (SHR). Adult male SHR were divided into vehicle-and EET-B (10 mg/kg/day, p.o., 9 weeks)-treated groups. After 2 weeks of treatment, rats were subjected to 30-min left coronary artery occlusion or sham operation. Systolic blood pressure (SBP) and echocardiography (ECHO) measurements were performed at the beginning of study, 4 days before, and 7 weeks after MI. At the end of the study, tissue samples were collected for histological and biochemical analyses. We demonstrated that EET-B treatment did not affect blood pressure and cardiac parameters in SHR prior to MI. Fractional shortening (FS) was decreased to 18.4 +/- 1.0% in vehicle-treated MI rats compared with corresponding sham (30.6 +/- 1.0%) 7 weeks following MI induction. In infarcted SHR hearts, EET-B treatment improved FS (23.7 +/- 0.7%), markedly increased heme oxygenase-1 (HO-1) immunopositivity in cardiomyocytes and reduced cardiac inflammation and fibrosis (by 13 and 19%, respectively). In conclusion, these findings suggest that EET analog EET-B has beneficial therapeutic actions to reduce cardiac remodeling in SHR subjected to MI.
Permanent Link: http://hdl.handle.net/11104/0296331